Comparing Budesonide Via MAD or INSI Prospective Cohort Study
Status:
Not yet recruiting
Trial end date:
2021-02-03
Target enrollment:
Participant gender:
Summary
Chronic Rhinosinusitis (CRS) is a common disorder in North America, affecting more than 31
million people annually. Common therapy for CRS includes intranasal corticosteroids (INCS)
such as budesonide. At our centre , the current practice is to administer budesonide two
ways: the mucosal atomization device (MAD), which is a nasal spray or impregnated budesonide
in nasal saline irrigation (INSI), which is a nasal rinse. Our study aims to see which method
of administering budesonide has the best treatment outcomes after sinus surgery. This study
will follow patients over a six-month period of time.